Amplifier Therapeutics to Present Preclinical Data of ATX-304 in Combination With Semaglutide at ENDO 2025
3 mins to read
July 11, 2025
New York – July 11, 2025 – Amplifier Therapeutics, a Cambrian Bio pipeline company, today announced new preclinical data to be presented at the Endocrine Society’s Annual Meeting (ENDO 2025), taking place July 12–15 at the Moscone Convention Center in San Francisco. The oral presentation will highlight the efficacy of ATX-304 in two studies investigating effects on body weight, food intake, and body composition in a mouse model of diet-induced obesity with ATX-304 dosed as monotherapy, in combination with semaglutide, and after semaglutide withdrawal.
ATX-304 is a novel, peripherally restricted, oral small molecule AMPK and mitochondrial activator in clinical development for obesity.
Presentation Information:
Weight Loss and Change in Body Composition in a DIO Mouse Model by the Combined AMPK and Mitochondrial Activator, ATX-304, Alone, in Combination With Semaglutide, and After Semaglutide Withdrawal
Abstract #: OR22-05
Date/Time: Sunday, July 13, 2025, 2:30–2:45 PM PT
Location: Room 208, Moscone Convention Center, San Francisco, California
Session: Adipose Tissue, Appetite, and Obesity: From Biology to Behavior: Addressing the Spectrum of Obesity-Related Issues
Presenter: James Peyer, PhD., Executive Chairman, Amplifier Therapeutics; CEO and Founder, Cambrian Bio
About ATX-304
ATX-304 is a novel, peripherally restricted, oral small molecule AMPK and mitochondrial activator currently in clinical development for obesity and other cardiometabolic disease.
About Cambrian Bio and Amplifier Therapeutics
Cambrian Bio (“Cambrian”) is a clinical-stage drug development company focused on building therapeutics to treat and ultimately prevent some of today’s most debilitating chronic diseases. Each program at Cambrian is led by its own R&D team in collaboration with experts dedicated to a pipeline company. This model allows Cambrian to develop new drugs efficiently, partner flexibly across the healthcare ecosystem, and reward the scientists whose vision drives the creation of new medicines.
Amplifier TX AB, doing business as Amplifier Therapeutics, is a Sweden-based biopharmaceutical pipeline company within Cambrian. It is focused on developing AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging, including metabolic conditions, cardiovascular disease, kidney disease, and cancer. Its lead asset, ATX-304, is currently in human clinical trials.
Contact
Claudia Pareja